Lp-PLA2 as a promising predictor of comorbidities in patients with severe psoriasis. (3rd July 2020)

• Record Type: Journal Article
• Authors: Kiluk, Paulina; Baran, Anna; Świderska, Magdalena; Maciaszek, Magdalena; Flisiak, Iwona
• Is Part Of: Journal of dermatological treatment. Volume 31:Number 5(2020)
• Page Start: 524
• Page End: 530
• Publication Date: 2020-07-03
• Subjects: Psoriasis -- lipoprotein-associated phospholipase A2 -- atherosclerosis -- cardiovascular disease; Skin -- Diseases -- Treatment -- Periodicals; Skin Diseases -- drug therapy -- Periodicals; Skin Diseases -- therapy -- Periodicals; 616.5
• DOI: 10.1080/09546634.2019.1606887
• Languages: English
• ISSNs: 0954-6634

Abstract

Abstract: Objective: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a well- known risk factor of atherosclerotic vascular diseases which are common comorbidities in psoriasis. The aim of this study was to evaluate serum Lp-PLA2 level in psoriatic patients and elucidate possible associations with disease activity, metabolic or inflammatory parameters and systemic treatment. Methods: We enrolled 33 patients with active plaque-type psoriasis and 11 healthy controls. Blood samples were collected before and after 3 months of systemic treatment with acitretin or methotrexate. Serum Lp-PLA2 level were evaluated by enzyme-linked immunosorbent assay. Results: Serum Lp-PLA2 level in patients with psoriasis did not statistically differ comparing to the control group ( p = .2). However, in patients with severe psoriasis Lp-PLA2 was significantly higher than in the controls before and after treatment ( p = .03, p = .01, respectively). The lipase did not correlate with BMI ( p = .22); however, a statistical significance was noted between psoriatics with obesity compared to the controls ( p = .03). No significant effect of systemic treatment combined ( p = .5) nor separately with acitretin ( p = .5) or methotrexate ( p = .1) on the Lp-PLA2 level was found, despite clinical improvement. Conclusion: Lp-PLA2 assay might be helpful in assessment of the risk of cardiometabolic comorbidities development especially in patients with severe psoriasis and obesity.